osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['lcsm,(-blcsm)', 'lung', 'lazertinib', 'sclc', 'nsclc', 'chrysalis-2']
#asco22 day 1: #lungcancer highlights 5/6
chrysalis-2: #amivamtamab+lazertinib post osi &amp; chemo in egfr+ nsclc n=162 orr 33% mdor 9.6 mo mpfs 5.1 mos mos 14.8 mos mariposa phiii il trials ongoing #lcsm #medtwitter 
Associate Director Community Outreach- Thoracic Oncology-University of Miami @SylvesterCancer , Boricua en la Luna, Tweets are my own. (she/her)